[The value of antibiotic prophylaxis using cefotetan in high-risk abdominal hysterectomy. Apropos of a prospective randomized study of 71 patients]. / Intérêt de l'antibioprophylaxie par le cefotetan dans les hystérectomies abdominales à risques. A propos d'une étude prospective par tirage au sort portant sur 71 patientes.

The advantage of antibiotic prophylaxis using a single dose of 2 g of cefotetan, administered during the induction of anesthesia, was studied in 71 patients undergoing an abdominal hysterectomy and presenting at least one of the following risk factors: obesity or procedure exceeding two hours. After random selection, 33 patients were treated, 38 were not and constitute the reference group. Comparison between the two groups shows a significant difference concerning the general morbidity, post-operative fever, urinary infection and abdominal wall abscess. Considering the excellent tolerance of the treatment and the fact that it is easy to use and inexpensive, antibiotic prophylaxis with cefotetan is quite interesting for this type of surgery.

[Prospective randomized study comparing the efficacy and tolerance of clindamycin-gentamycin versus metronidazole-gentamycin in acute utero-adnexal infections in hospitalized patients]. / Essai prospectif randomisé comparant l'efficacité et la tolérance de la clindamycine-gentamycine versus métronidazole-gentamycin dans les infections utéro-annexielles aiguës chez des patientes hospitalisées.

The efficacy and safety of two antibiotic combination (clindamycin + gentamycin [C + G] versus metronidazole + gentamycin [M + G]) have been compared in 45 in-patients suffering from pelvic inflammatory disease in a clinical prospective randomized trial. The rates of clinical and bacteriological recovery reached respectively 85.7% and 71.4% for C + G group compared to 83.3% and 78.6% for M + G group (no significant differences). Side effects (vomiting, gastralgia and vaginal mycosis) developed in four occasions in each group. The most frequently isolated organisms were chlamydiae, E. coli and Neisseria gonorrheae (around 50% of overall isolated organisms). Due to the lack of significant differences between the two antibiotic combinations, the final choice will depend on potential risks generated by these products.